Is Bayer Schering Pharma conducting further clinical studies?
Bayer Schering Pharma has initiated and supports a series of different studies with Testogel® and Nebido® with the aim to further elaborate the efficacy and safety of testosterone on a variety of conditions related to hypogonadism. These studies include two long-term, placebo-controlled studies in patients with LOH (Late-Onset Hypogonadism), one study in elderly frail men, one study in hypogonadal men with the metabolic syndrome, and one study in men with erectile dysfunction who do not respond adequately to PDE-5 inhibitors. Furthermore, several studies were initiated by external sponsors testing the effect of Nebido® in hypogonadal men with comorbidities such as metabolic syndrome, type 2 diabetes, and cardiovascular disease. There is meanwhile a wealth of publications available from all these studies.
